Use of Immun Checkpoint Inhibitor Ipilimumab in Renal Transplant Patients with Advanced Cancer: Is Risk/Benefit Ratio Dilemma?

Sürdürülebilir Kalkınma Amaçları

• SKA 3: Sağlıklı Bireyler

Atıf için künye

Aykaç, M., & Balkan, E. (2020). Use of Immun Checkpoint Inhibitor Ipilimumab in Renal Transplant Patients with Advanced Cancer: Is Risk/Benefit Ratio Dilemma? New Trends in Medicine Science, 1(2), 137–145.

@article{aykac2020-235706,
  author = {Aykaç, Merve and Balkan, Eda},
  title = {Use of Immun Checkpoint Inhibitor Ipilimumab in Renal Transplant Patients with Advanced Cancer: Is Risk/Benefit Ratio Dilemma?},
  journal = {New Trends in Medicine Science},
  year = {2020},
  volume = {1},
  number = {2},
  pages = {137--145},
  issn = {2717-8161},
  url = {https://akademik.atauni.edu.tr/yayinlar/235706-use-of-immun-checkpoint-inhibitor-ipilimumab-in-renal-transplant-patients-with}
}